Home New Customer? Create Account
Member Login:

IRES Expression Plasmids

OG291 - pSF-CMV-FMDV-Puro

PRICE

Starting at: $347.00

Please Choose:

Shipping Option



Enter Quantity:



This plasmid is compatible with all of the other DNA sequences available on this site, which are all sold in the same backbone. This flexibility allows you to create any vector you require, with a variety of functions, simply by compiling the relevant sections from our product range.

Vector: pSF-CMV-FMDV-Puro

Product Code: OG291

Quantity Provided:  5µg

Size (bp): 5316

Bacterial Antibiotic Selection: Kanamycin

Origin and Compatibility: pUC high copy, derived from pBR322   

Copy Number: 500-700 copies per cell

Promoter: Cytomegalovirus (CMV) immediate early promoter.

Purpose: This vector allows the expression of two genes from one vector, where the second gene produced from the mRNA is the puromycin antibiotic resistance gene (puro) under the control of the internal ribosome entry site (IRES) from Foot and Mouth Disease virus (FMDV). Transcription is driven by the CMV promoter. There is a multiple cloning site immediately downstream of the CMV promoter which is then            followed by the IRES element driving the puro gene.     

Quality Validation: This vector has been demonstrated to express reporter genes to high levels under the CMV promoter, and express puro to high levels under the control of the downstream IRES. The level of expression of the second gene (puro) is significantly lower (approximately 30-40-fold) than the level of expression achieved from the CMV promoter using cap-dependent mechanism. However, the level of expression from the IRES under the CMV promoter in this vector is still higher than many other constitutive promoters, such as SV40, using cap-dependent translation mechanisms in a range of cell lines. The reporter genes under the CMV promoter were inserted into the NcoI site and XbaI site, with the start codon and stop codon residing within each of these sites, respectively. The puro resistance gene placed under the control of the IRES was inserted into the PciI site and the NheI site of pSF-CMV-FMDV-PciI. The stop codon of the Puro gene is upstream of the NheI site. Reporter gene expression and puromycin resistance was validated in 293 cells.   

Quality Sequencing Analysis: This vector has been fully sequenced using primers F1-F10. The sequences and details of these primers are available through our website.

Intellectual Property Status: According to our IP-friendly policy, this plasmid is sold free of reach-through rights on any derivatives you may create.

Genetic Modifications to standard parts:

  • CMV promoter – An NcoI site has been ablated in the CMV promoter. This change does not reduce expression.
  • KanR cassette – This KanR resistance region is not a wild type sequence, it has been modified to remove all restriction sites that conflict with the SnapFastTM system and to retain a high level of antibiotic resistance. It has been validated in E.coli.  
  • Puromycin resistance Gene – The puro gene has been modified to remove a StuI site and an EagI site to ensure compatibility with all of our products. These are all conservative changes and do not change the amino acid sequence.   

Restriction site notes:

  • Bgl2, SwaI, and PmeI each cut the vector at two sites positioned to flank the promoter, origin, and KanR, respectively.
  • The FMDV IRES contains a range of sites that conflict with the SnapFast system, including KpnI (2 additional sites) XbaI (1 site), Eag1 (1 site), Hind3 (1 site) and BseRI (1 site). It is unlikely that all of these sites can be removed because of the complex structural nature of the IRES RNA.
  • BsgI and BseRI recognise non-palindromic DNA sequences and cleave upstream of their recognition sites, within the stop codon that is found inside the XbaI restriction site. However, BseRI also cuts within the IRES in this plasmid.